Highlights
- PRMT9 expression is significantly upregulated in human and murine peripheral blood mononuclear cells during the acute phase of myocardial infarction (MI).
- Macrophage-specific PRMT9 deficiency exacerbates post-MI cardiac damage by promoting M1-like proinflammatory polarization, while its overexpression facilitates inflammation resolution and functional recovery.
- Mechanistically, PRMT9 catalyzes the symmetric dimethylation of STAT1 at residues R588 and R736, triggering its ubiquitination and subsequent selective autophagic degradation via the p62/NDP52 pathway.
- Pharmacological inhibition of STAT1 with fludarabine can rescue the adverse cardiac phenotype induced by PRMT9 loss, highlighting a potential translational pathway for clinical intervention.
Background
Acute Myocardial Infarction (AMI) remains a leading cause of morbidity and mortality worldwide, characterized by the sudden loss of cardiomyocytes and a subsequent intense inflammatory response. The post-MI landscape is heavily influenced by the infiltration and activation of macrophages. These cells exhibit significant plasticity, shifting between a proinflammatory (M1-like) state, which aids in debris clearance but can cause collateral tissue damage, and an anti-inflammatory (M2-like) state, which promotes tissue repair and remodeling.
A major clinical challenge in MI management is the prevention of excessive or prolonged M1-like activity, which drives adverse ventricular remodeling and heart failure. Recent evidence has pointed toward epigenetic modifications, particularly protein arginine methylation, as key regulators of immune cell fate. Protein Arginine Methyltransferases (PRMTs) typically modify proteins via asymmetric dimethylation; however, PRMT9 is a distinct member of the family that facilitates symmetric dimethylation. Until recently, its role in cardiovascular pathophysiology remained largely obscure.
Key Content
PRMT9 Expression Dynamics in Human and Murine MI
In a comprehensive study published in Circulation (2026), Bai et al. utilized transcriptomic data (GSE166780) and clinical samples to map the expression of PRMT9 during the early stages of MI. The researchers observed a marked increase in PRMT9 levels within peripheral blood mononuclear cells (PBMCs) of both patients and murine models shortly after the ischemic event. This early induction suggested a compensatory or regulatory role for PRMT9 in response to acute cardiac stress.
Functional Consequences of PRMT9 Modulation
To delineate the functional importance of this enzyme, the researchers employed macrophage-specific Prmt9 knockout (KO) mice and adeno-associated virus (AAV) vectors for macrophage-targeted overexpression. The results were stark:
- Loss of Function: PRMT9 deficiency led to a significant expansion of M1-type macrophages in the heart, increased secretion of proinflammatory cytokines (e.g., TNF-α, IL-6), larger infarct sizes, and poorer systolic function compared to wild-type controls.
- Gain of Function: Conversely, overexpressing PRMT9 in macrophages mitigated the inflammatory storm, reduced the area of myocardial necrosis, and significantly improved long-term cardiac output and ejection fraction.
The PRMT9-STAT1 Signaling Axis
The study’s central mechanistic discovery involves the Signal Transducer and Activator of Transcription 1 (STAT1), a master regulator of M1 macrophage polarization. Transcriptome and immunoprecipitation/mass spectrometry (IP/MS) analyses revealed that PRMT9 directly binds to STAT1. Unlike other PRMTs that might activate STAT1, PRMT9 catalyzes symmetric dimethylation at two specific arginine residues: R588 and R736.
This methylation event does not merely alter STAT1’s transcriptional activity; it marks the protein for destruction. The study found that symmetrically dimethylated STAT1 is susceptible to ubiquitination. This ubiquitination then recruits selective autophagy receptors, specifically SQSTM1/p62 and NDP52/CALCOCO2, which guide STAT1 to the lysosome for degradation. This process, termed “autophagic degradation of STAT1,” effectively limits the pool of STAT1 available to drive proinflammatory gene expression, thereby dampening the M1 response.
Pharmacological Rescue and Clinical Implications
Crucially, the researchers tested whether the deleterious effects of PRMT9 loss could be reversed pharmacologically. They utilized fludarabine, a clinically approved chemotherapeutic agent known to inhibit STAT1 activation. In Prmt9-deficient mice, fludarabine treatment successfully suppressed the excessive M1 polarization and rescued the cardiac phenotype, reducing infarct size and improving survival. This finding provides a proof-of-concept for targeting the STAT1 pathway in patients who may have low PRMT9 activity or excessive inflammatory responses post-MI.
Expert Commentary
The discovery of the PRMT9-STAT1-autophagy axis represents a significant leap in our understanding of how the heart regulates its own inflammatory fire. Most research in the PRMT field has focused on Type I PRMTs (like PRMT1), which often promote inflammation. PRMT9, as a Type II enzyme, acts as a critical “molecular brake.”
The therapeutic potential of this pathway is multifaceted. First, PRMT9 levels in PBMCs could serve as a biomarker for the inflammatory state of an MI patient. Second, the use of STAT1 inhibitors like fludarabine—or the development of more specific STAT1 degraders—could offer a targeted way to prevent adverse remodeling. However, a major hurdle remains the delivery of these agents. While AAV-based overexpression works well in a lab setting, clinical translation will require refined delivery systems to ensure that macrophage modulation occurs primarily within the infarcted tissue without inducing systemic immunosuppression.
Furthermore, the interplay between different degradation pathways (proteasomal vs. autophagic) for STAT1 deserves further study. The identification of R588 and R736 as the critical regulatory sites opens the door for small-molecule stabilizers that might mimic the effect of PRMT9 methylation.
Conclusion
The study by Bai et al. identifies PRMT9 as a vital endogenous protector against excessive myocardial injury following acute infarction. by promoting the symmetric dimethylation and selective autophagic degradation of STAT1, PRMT9 limits the proinflammatory M1 macrophage response, thereby preserving cardiac structure and function. Future research should focus on translating these epigenetic insights into bedside therapies, potentially through the repurposing of STAT1 inhibitors or the development of PRMT9 mimetics to improve outcomes for patients with acute coronary syndromes.
